This page explains how NK cell, MSC, and EV-related options are reviewed through records, testing, physician consultation, informed consent, cost confirmation, and risk explanation. Suitability and treatment details are determined individually after physician review.
We do not present regenerative medicine as a one-size-fits-all treatment. Records, test results, medical history, risks, and alternatives are reviewed before any option is discussed.
Blood panel (incl. infectious disease screening), inflammatory biomarkers, immune profiling, and MRI imaging. An objective picture of your cellular environment drives every protocol decision.
NK cells are studied in the context of immune surveillance. If considered, infection screening, medical history, and general condition are reviewed before a physician determines whether it is appropriate.
MSC and EV-related services are possible options only after review. They do not promise improvement, and additional testing, specialist referral, or no treatment may be the appropriate next step.
Natural Killer (NK) cells are part of the immune system's surveillance function. Research discusses their relationship with abnormal cells and senescent-cell biology, but treatment suitability is reviewed individually through physician consultation.
Before any NK discussion, the clinic reviews medical history, cancer history, current treatment status, medications, infection-screening results, general condition, and whether standard specialist care should be prioritized.
NK cell therapy is filed under Japan's Act on Safety of Regenerative Medicine (Act No. 85 of 2013) — Plan No. PB3250244 — and reviewed by the Certified Committee for Regenerative Medicine of the Japan Society for Cell Immunology.
View dedicated page arrow_forwardNK cells recognize NKG2D ligands and PVR/Nectin-2 expressed on senescent cell surfaces. Perforin and granzyme B are released to induce apoptosis. Research suggests selective targeting with limited impact on healthy cells.
Inflammation, immune context, cancer history, and current treatment status are reviewed before NK-related consultation. Specialist care remains the priority when indicated.
Administered via intravenous drip for systemic distribution. Protocol is tailored to individual condition and goals — one or multiple sessions. Individual results vary.
Filing Information: NK Cell Therapy — filed / notified under Japan's Act on Safety of Regenerative Medicine. Plan No. PB3250244. Filing is not a national efficacy or safety endorsement.
Beyond direct differentiation, MSCs exert paracrine effects through secretion of TGF-β, HGF, IGF-1, and anti-inflammatory cytokines. Research suggests action on cartilage, synovium, and tendon tissue.
For osteoarthritis consultation, MRI, symptoms, function, medications, and orthopedic context are reviewed before considering intra-articular administration under PB3240166 / PB3250155. Individual results vary.
For chronic pain consultation, history, imaging, inflammatory context, medications, and specialist-care needs are reviewed before considering intravenous administration under PB3240161 / PB3250154. Individual results vary.
Filing Information: MSC plans include chronic pain PB3240161 / PB3250154 and osteoarthritis PB3240166 / PB3250155. Out-of-pocket; not covered by public health insurance.
MSC consultation at CFO is centered on autologous adipose-derived cell plans. The physician reviews whether an intravenous route for chronic pain or an intra-articular route for osteoarthritis is appropriate, or whether referral / follow-up without regenerative medicine is the safer next step.
If multiple options are considered, sequence and scope are designed individually after reviewing test results, medical history, goals, and risks.
MSC therapy is considered within filed Category II provision plans under Japan's Act on Safety of Regenerative Medicine. Filing describes the provision framework and is distinct from national treatment-effect endorsement.
Knee MRI Evaluation (autologous adipose-derived MSC suitability review) →
Extracellular vesicles (EV) are nano-scale particles secreted by cells, carrying mRNA, miRNA, and proteins to neighboring cells. Research suggests EVs transmit signals for tissue repair, inflammation regulation, and cellular activation.
EV and exosome research discusses cell-to-cell signaling, inflammation, and tissue-repair pathways. This does not establish an individual indication or a promised outcome.
EV / exosome-related topics are reviewed separately by the physician and are not presented as a promised regenerative-medicine result. Purpose, route, risks, costs, and alternatives require individual explanation.
Research Context: EVs and exosomes are an actively evolving field of study. Public explanations are research background only; full informed consent and physician review are required before any related service is considered.
Physician evaluation: medical history, current condition, and goals. Protocol design, cost outline, schedule, and informed consent covering benefits and risks.
Blood panel for HIV, syphilis, hepatitis B and C prior to any cell-therapy consideration. Results are confirmed before the physician determines the next step.
The physician reviews candidate options, sequence, route, and non-treatment alternatives based on records, testing, medical history, and risk discussion.
Post-treatment biomarker reassessment and progress monitoring. Additional sessions considered as needed. Remote follow-up available online for international patients.
The following are consultation areas. Suitability, route, referral needs, and whether no regenerative-medicine procedure is appropriate are assessed by the physician.
For osteoarthritis and knee pain, MRI, symptoms, function, and orthopedic context are reviewed before considering intra-articular MSC administration or referral.
For chronic pain, records, imaging, inflammation context, and medications are reviewed before considering intravenous MSC administration or another medical path.
Bloodwork, imaging, symptoms, immune context, and medical history are organized before any upper option is discussed. The next step may be testing, follow-up, referral, or physician consultation.
If cancer history or current oncology care is relevant, specialist care and standard treatment remain the priority. NK-related consultation is reviewed individually and is not a substitute for cancer treatment.
Aesthetic or supportive EV / exosome-related topics are handled as separate physician review. Purpose, route, risks, costs, and alternatives are explained individually.
All treatments described on this page are out-of-pocket (self-pay) medical services. They are not covered by Japan's public health insurance system.
NK cell therapy is filed under Japan's Act on Safety of Regenerative Medicine (Plan No. PB3250244). MSC plans include chronic pain (PB3240161 / PB3250154) and osteoarthritis (PB3240166 / PB3250155).
"Filed / notified" denotes that the required provision framework has been established under this Act. It does not represent national endorsement of individual treatment effect.
Individual results vary. A specific outcome is not promised.
Full informed consent is provided by the physician prior to any treatment, covering benefits, potential risks, and alternatives.
Please bring any questions to your initial consultation — we are happy to address them in detail.
At your initial consultation, our physician reviews records, testing needs, route, risks, alternatives, and a cost overview. International inquiries are welcome via WhatsApp.